Measuring the Symptom Burden Associated with the Treatment of Chronic Myeloid Leukemia

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2013 Jun 20

PMID 23777764

Citations 50

Authors

Loretta A Williams

Araceli G Garcia Gonzalez

Patricia Ault

Tito R Mendoza

Mary L Sailors

Janet L Williams

Furong Huang

Aziz Nazha

Hagop M Kantarjian

Charles S Cleeland

Jorge E Cortes

Affiliations

Soon will be listed here.

Abstract

We developed a module of the MD Anderson Symptom Inventory (MDASI) for patients with chronic myeloid leukemia (CML). To develop the MDASI-CML, we identified CML-specific symptoms from qualitative interviews with 35 patients. A list of candidate symptoms was reduced by a panel of patients, caregivers, and clinicians to the 13 core MDASI symptom items and 6 CML-specific items; these items were subsequently administered to 30 patients. Cognitive debriefing confirmed that the items were clear, relevant, and easy to use. One additional CML-specific symptom item was added, for a total of 7. The refined MDASI-CML was administered to 152 patients once every 2 weeks for 1 year. The content, concurrent, known-group, and construct validity of the MDASI-CML were evaluated. The internal consistency and test-retest reliabilities of the module were adequate. Longitudinal analysis showed relatively stable symptom severity scores over time. The most severe symptoms were fatigue, drowsiness, disturbed sleep, muscle soreness and cramping, and trouble remembering things. Approximately one-third of the patients who completed the MDASI-CML reported persistent moderate-to-severe symptoms. The MDASI-CML is a valid and reliable symptom assessment instrument that can be used in clinical studies of symptom status in patients with CML.

Citing Articles

The efficacy of lavender oil on fatigue and sleep quality in patients with hematological malignancy receiving chemotherapy: a single-blind randomized controlled trial.

Yildirim D, Harman Ozdogan M, Erdal S, Selcuk S, Guneri A, Simsek E Support Care Cancer. 2025; 33(2):79.

PMID: 39775962 PMC: 11711766. DOI: 10.1007/s00520-024-09143-5.

Quality of Life and Symptoms of Hospitalized Hematological Cancer Patients.

Konstantinidis T, Tsatsou I, Tsagkaraki E, Chasouraki E, Saridi M, Adamakidou T Curr Oncol. 2024; 31(11):6699-6710.

PMID: 39590125 PMC: 11592878. DOI: 10.3390/curroncol31110494.

Mutations in Genes Producing Nitric Oxide and Hydrogen Sulfide and Their Connection With Apoptotic Genes in Chronic Myeloid Leukemia.

Saber B, Aygan A, Salihi A Cureus. 2024; 16(6):e61570.

PMID: 38962618 PMC: 11221202. DOI: 10.7759/cureus.61570.

WeChat assisted electronic symptom measurement for patients with adenomyosis.

Xu W, Zhang X, Xu F, Yuan Y, Tang Y, Shi Q BMC Med Inform Decis Mak. 2024; 24(1):168.

PMID: 38886791 PMC: 11181603. DOI: 10.1186/s12911-024-02570-8.

The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia.

Saez Perdomo M, Stuckey R, Gonzalez-Perez E, Sanchez-Sosa S, Estupinan-Cabrera P, Lakhwani Lakhwani S Hematol Rep. 2024; 16(1):140-150.

PMID: 38534885 PMC: 10970168. DOI: 10.3390/hematolrep16010015.

References

Aziz Z, Iqbal J, Aaqib M, Akram M, Saeed A . Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma. 2011; 52(6):1017-23. DOI: 10.3109/10428194.2011.560310. View

Kirkova J, Davis M, Walsh D, Tiernan E, OLeary N, LeGrand S . Cancer symptom assessment instruments: a systematic review. J Clin Oncol. 2006; 24(9):1459-73. DOI: 10.1200/JCO.2005.02.8332. View

Huang X, Cortes J, Kantarjian H . Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012; 118(12):3123-7. PMC: 3342429. DOI: 10.1002/cncr.26679. View

Stalfelt A, ZETTERVALL O . Quality of life in young patients with chronic myelocytic leukaemia during intensive treatment including interferon. Leuk Res. 1997; 21(8):775-83. DOI: 10.1016/s0145-2126(97)00026-x. View

Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F . Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011; 118(17):4554-60. DOI: 10.1182/blood-2011-04-347575. View

Spitzer W, Dobson A, Hall J, Chesterman E, Levi J, Shepherd R . Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis. 1981; 34(12):585-97. DOI: 10.1016/0021-9681(81)90058-8. View

Rosenthal D, Mendoza T, Chambers M, Asper J, Gning I, Kies M . Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck. 2007; 29(10):923-31. DOI: 10.1002/hed.20602. View

Savage D, Szydlo R, Goldman J . Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol. 1997; 96(1):111-6. DOI: 10.1046/j.1365-2141.1997.d01-1982.x. View

Armstrong T, Mendoza T, Gning I, Gring I, Coco C, Cohen M . Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). J Neurooncol. 2006; 80(1):27-35. DOI: 10.1007/s11060-006-9135-z. View

10.

Cleeland C, Mendoza T, Wang X, Chou C, Harle M, Morrissey M . Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000; 89(7):1634-46. DOI: 10.1002/1097-0142(20001001)89:7<1634::aid-cncr29>3.0.co;2-v. View

11.

Sloan J, Loprinzi C, Kuross S, Miser A, OFallon J, Mahoney M . Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol. 1998; 16(11):3662-73. DOI: 10.1200/JCO.1998.16.11.3662. View

12.

Mendoza T, Wang X, Lu C, Palos G, Liao Z, Mobley G . Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory. Oncologist. 2011; 16(2):217-27. PMC: 3228083. DOI: 10.1634/theoncologist.2010-0193. View

13.

Gning I, Trask P, Mendoza T, Harle M, Gutierrez K, Kitaka S . Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory. Oncology. 2008; 76(1):59-68. DOI: 10.1159/000178809. View

14.

Efficace F, Cartoni C, Niscola P, Tendas A, Meloni E, Scaramucci L . Predicting survival in advanced hematologic malignancies: do patient-reported symptoms matter?. Eur J Haematol. 2012; 89(5):410-6. DOI: 10.1111/ejh.12004. View

15.

Postel-Vinay S, Gomez-Roca C, Molife L, Anghan B, Levy A, Judson I . Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?. J Clin Oncol. 2011; 29(13):1728-35. DOI: 10.1200/JCO.2010.31.9236. View

16.

Hahn E, Glendenning G, Sorensen M, Hudgens S, Druker B, Guilhot F . Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol. 2003; 21(11):2138-46. DOI: 10.1200/JCO.2003.12.154. View

17.

Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M . Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009; 101(23):1624-32. PMC: 2786917. DOI: 10.1093/jnci/djp386. View

18.

Trask P, Cella D, Powell C, Reisman A, Whiteley J, Kelly V . Health-related quality of life in chronic myeloid leukemia. Leuk Res. 2012; 37(1):9-13. DOI: 10.1016/j.leukres.2012.09.013. View

19.

Pinilla-Ibarz J, Cortes J, Mauro M . Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications. Cancer. 2010; 117(4):688-97. DOI: 10.1002/cncr.25648. View

20.

Trask P, Cella D, Besson N, Kelly V, Masszi T, Kim D . Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res. 2011; 36(4):438-42. DOI: 10.1016/j.leukres.2011.10.011. View